- Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patientsPia Wegman
Department of Biomedicine and Surgery, Division of Cellbiology, Faculty of Health Sciences, Linkoping, Sweden
Breast Cancer Res 7:R284-90. 2005..We therefore investigated the genotypes of CYP2D6 and SULT1A1 in 226 breast cancer patients participating in a trial of adjuvant tamoxifen treatment in order to validate the benefit from the therapy...
- CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author responsePia P Wegman
Breast Cancer Res 7:E7. 2005
- Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancerPia Wegman
Department of Biomedicine and Surgery, Division of Cell Biology, Faculty of Health Sciences, Linkoping University, 581 85 Linkoping, Sweden
Breast Cancer Res 9:R7. 2007....
- p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patientsPia Wegman
Division of Cell Biology, Department of Biomedicine and Surgery, Faculty of Health Sciences, 581 85 Linkoping, Sweden
Pharmacogenet Genomics 16:347-51. 2006..The p53 protein is a key determinant to induce either growth arrest or apoptosis in response to cytotoxic stress...